Replacing What Parkinson’s Disease Takes Away
Parkinson’s disease develops as dopamine-producing neurons in the brain are progressively lost. Because dopamine plays an important role in controlling movement, this loss can contribute to symptoms such as tremors, stiffness, and slowed movement.
Medications can help replace or mimic dopamine activity, but researchers are also exploring an entirely different strategy: replenishing the cells responsible for producing dopamine in the first place.
A 2025 Phase I/II clinical trial published in Nature investigated whether dopamine-producing cells developed from induced pluripotent stem cells (iPSCs) could safely survive and function after being transplanted into the brains of people with Parkinson’s disease.
How the Study Worked
The trial was conducted at Kyoto University Hospital and included seven patients between the ages of 50 and 69. Researchers created dopaminergic progenitor cells from iPSCs. These are immature cells that have been guided toward becoming dopamine-producing neurons. The cells were then transplanted into an area of the brain called the putamen, which is closely involved in movement and is strongly affected by dopamine loss in Parkinson’s disease.
Patients received either a lower or higher cell dose and were monitored for 24 months. Six patients were included in the study’s effectiveness analysis, while all seven were evaluated for safety.
Researchers used neurological assessments along with MRI and PET imaging to determine whether the transplanted cells survived, produced dopamine, and influenced motor function.
Encouraging Signs After Two Years
One of the most important findings was that the transplanted cells appeared capable of surviving and functioning within the brain.
PET imaging showed that dopamine activity in the putamen increased by an average of 44.7% after 24 months, with an even larger increase observed in the higher-dose group.
Researchers also saw encouraging changes in movement assessments:
- Four of six patients showed improvement in motor function when evaluated without Parkinson’s medication.
- Five of six patients improved when evaluated while taking medication.
- Four patients improved on the Hoehn–Yahr scale, which is commonly used to describe the severity of Parkinson’s-related movement difficulties.
For motor assessments performed without medication, scores improved by an average of 20.4% after 24 months.
An Important Focus on Safety
Safety was the primary focus of this early-stage trial. There were no reports of serious adverse events requiring hospitalization or resulting in death during the study. MRI monitoring also found no evidence of abnormal tumor-like growth from the transplanted cells.
Importantly, imaging showed that the transplanted cells survived over the two-year follow-up period without uncontrolled growth. The researchers also found evidence that the cells were producing dopamine within the targeted area of the brain.
Participants did experience mild to moderate adverse events, and changes in involuntary movements were observed during follow-up. Researchers emphasized that longer-term monitoring will remain important as this approach continues to be studied.
Why iPSCs Are So Interesting
Induced pluripotent stem cells have a unique role in regenerative medicine. They are created by reprogramming mature adult cells into a flexible state where they can be guided to develop into specialized cell types.
In this trial, researchers directed iPSCs toward becoming dopaminergic progenitor cells, which are cells capable of maturing into the dopamine-producing neurons that Parkinson’s disease gradually damages.
Rather than focusing only on managing symptoms, this approach explores whether regenerative medicine could potentially restore some of the biological function that has been lost.
A Step Forward for Regenerative Neurology
This Phase I/II trial was small and did not include a placebo comparison group, so larger controlled studies will be needed to better determine how effectively this therapy may improve Parkinson’s symptoms.
After two years, the transplanted iPSC-derived cells survived without tumor formation, showed evidence of producing dopamine, and were accompanied by improvements in motor function in several patients.
These results provide encouraging human evidence that stem cell-derived dopamine-producing cells may offer a new direction for regenerative research in Parkinson’s disease, while giving researchers valuable information for larger clinical trials to come.
Source
Sawamoto N, Doi D, Nakanishi E, et al. Phase I/II trial of iPS-cell-derived dopaminergic cells for Parkinson’s disease. Nature. 2025;641:971–977. Available from: https://www.nature.com/articles/s41586-025-08700-0
Related Treatment Pages